Marinova Amanda M, Reilly Jennifer L, Wong Victoria, Weiss Stephanie, Olszanski Anthony J
Fox Chase Cancer Center, Philadelphia, Pennsylvania.
J Adv Pract Oncol. 2021 Jan-Feb;12(1):79-83. doi: 10.6004/jadpro.2021.12.1.6. Epub 2021 Jan 1.
Leptomeningeal disease in patients with melanoma historically portends a grim prognosis, with median survival measured in weeks to months. The advent of effective immunotherapy and targeted agents may modify the outcome of such patients. This case report describes a 43-year-old patient diagnosed with stage IIIa -positive cutaneous melanoma in 2012 who subsequently developed leptomeningeal involvement as her sole site of melanotic metastasis. She received multiple systemic therapies and radiotherapy and survived 2.5 years after her diagnosis with central nervous system involvement. This case report highlights the importance of a multidisciplinary team and the advent of effective agents, which offers the potential for significantly improved outcomes for patients with metastatic melanoma involving the central nervous system.
黑色素瘤患者的柔脑膜疾病在历史上预示着预后不佳，中位生存期以数周至数月计。有效免疫疗法和靶向药物的出现可能会改变这类患者的预后。本病例报告描述了一名43岁患者，2012年被诊断为IIIa期阳性皮肤黑色素瘤，随后出现柔脑膜受累，这是她黑色素转移的唯一部位。她接受了多种全身治疗和放疗，在被诊断为中枢神经系统受累后存活了2.5年。本病例报告强调了多学科团队的重要性以及有效药物的出现，这为涉及中枢神经系统的转移性黑色素瘤患者显著改善预后提供了可能性。
